CARLSBAD, Calif., Aug. 28 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR) today announced that due to the Labor Day holiday
and procedural delays in processing sales of its Class A Warrants, the Company
has extended the redemption date for its Class A Warrants from Wednesday
September 3, 2003 to Monday, September 8, 2003.  Holders of Class A Warrants
may avoid the redemption of their Class A Warrants by paying the exercise
price for their warrants to the Company's warrant agent, Computershare Trust
Company, Inc., prior to 5:00 P.M. Eastern Standard Time on Friday,
September 5, 2003, the last business day before the redemption date.
Furthermore, the Company has granted a "broker-protect" period through Friday,
September 26, 2003 to allow for the processing of paperwork in connection with
the exercise of the Class A Warrants; holders of Class A Warrants who deliver
funds for their exercise by the September 5, 2003 deadline must deliver their
warrants for settlement on or before the "broker-protect" period ends.
    If all of the outstanding Class A Warrants are exercised, Immune Response
would receive gross proceeds of approximately $3.1 million.  The exercise of
the warrants is part of the Company's plan to strengthen its financial
position in order to support the continuing clinical development of REMUNE(R),
a novel vaccine candidate for the treatment of HIV and AIDS.  REMUNE(R) is
currently being evaluated in a Phase II clinical study in Spain, and an
additional Phase II study is expected to commence in Italy later this year.
    The Company issued the Class A Warrants in its December 10, 2002 private
placement.  Each Class A Warrant is exercisable for one share of Common Stock
and one Class B Warrant at an initial exercise price of $1.33.  Additionally,
each Class B Warrant is exercisable for one share of Common Stock at an
initial exercise price of $1.77.  Unless exercised before redemption, holders
of Class A Warrants will receive $0.01 per Class A Warrant.
    After the redemption date, the rights of holders of Class A Warrants of
the Company, including, but not limited to, their right to sell, or to
exercise the Class A Warrants and receive common stock and Class B Warrants of
the Company upon such exercise, shall cease.  Only the right to receive from
the Company the redemption price for their Class A Warrants without interest
thereon will survive the redemption date.

    About The Immune Response Corporation and REMUNE(R)
    Co-founded by medical pioneer Dr. Jonas Salk and headquartered in
Carlsbad, California, The Immune Response Corporation is a biopharmaceutical
company dedicated to treating HIV and AIDS through the development of
REMUNE(R).  REMUNE(R) is an immune-based therapeutic vaccine designed to
induce an HIV-specific immune response and boost the body's natural defense
mechanisms in order to slow the virus' progression.  REMUNE(R) is comprised of
HIV that has been chemically killed and inactivated so that it is
non-infectious.  During the inactivation process, the HIV outer envelope,
which is prone to rapid mutations, is removed.  REMUNE(R) is then emulsified
in Incomplete Freund's Adjuvant, an agent that elicits a more potent immune
response by drawing the immune system's attention to the inactivated virus.
    HIV, the human immunodeficiency virus, is the virus that causes AIDS, a
condition that slowly destroys the body's immune system, making it vulnerable
to infections.  More than 60 million people have been infected with HIV since
it was first recognized in 1981.  Today, 40 million people around the world
are living with HIV.

    This news release contains forward-looking statements.  Actual results
could vary materially from those expected due to a variety of risk factors,
including whether holders will exercise their Class A Warrants, whether the
Company will continue as a going concern and successfully raise proceeds from
financing activities sufficient to fund operations and additional clinical
trials of REMUNE(R), the uncertainty of successful completion of any such
clinical trials, whether REMUNE(R) will be effective as either a preventive or
therapeutic vaccine, whether future trials will be conducted and whether the
results of such trials will coincide with the results of REMUNE(R) in
preclinical trials.  These risks, among others, are set forth in The Immune
Response Corporation's SEC filings including, but not limited to, its Annual
Report on Form 10-K for the year ended December 31, 2002, and subsequent
Quarterly Reports on Form 10-Q.  The Company undertakes no obligation to
publicly release the results of any revisions to these forward-looking
statements, which may be made to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events.

    REMUNE(R) is a registered trademark of The Immune Response Corporation.

    For further information, please contact:  media, Gwen Rosenberg,
+1-858-759-0759, or cell, +1-858-504-0759, or investors, Michael Jeub, CFO,
+1-760-602-5523, info@imnr.com, both of The Immune Response Corporation

Link to this page: